Technology

Illumina launches pilot proteomics program with UK Biobank and biopharma collaborators to analyze 50,000 samples

Published

11 hours ago

January 13, 2025

Study will generate a key reference data set with Illumina Protein Prep solution

SAN DIEGO, Jan. 13, 2025 /PRNewswire/ — Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced a pilot proteomics program to analyze 50,000 UK Biobank samples in collaboration with deCODE Genetics, Standard BioTools, Tecan, GSK, Johnson & Johnson, and Novartis. The pilot program is based on Illumina’s upcoming proteomics assay, Illumina Protein Prep™, powered by SOMAmer® technology, a next-generation sequencing (NGS) based solution that will help scale access to proteomic insights.

Proteomics enables the observation of direct cellular function to improve understanding of the role of proteins in health and disease, and facilitates biomarker discovery for conditions such as cancer and cardiovascular disease. Researchers use protein quantitative trait loci (pQTLs), which are emerging as a vital proteogenomic tool for drug discovery, linking genetic variation with protein expression data and disease or other phenotypes. With the advent of high-throughput proteomics methods such as Illumina Protein Prep, the discovery of new pQTLs is now more accessible.

“UK Biobank data has set the standard as a reference dataset for the omics community, and we’re excited to collaborate across the health care industry in this pilot study as we prepare to launch Illumina Protein Prep,” said Steve Barnard, PhD, chief technology officer of Illumina. “We believe the pilot program will generate a new collection of high-quality, NGS-based proteomics data for the research community and pharma partners to advance biological insights.”

UK Biobank will provide 50,000 samples from the same study participants who are included in the UK Biobank Pharma Proteomics Project, a separate research collaboration between the UK Biobank and 14 biopharmaceutical companies. deCODE Genetics will process the samples using the Illumina Protein Prep solution and NovaSeq™ X Plus system, and run analysis using the DRAGEN Protein Quantification pipeline. The first 30,000 samples are funded through coinvestment from Illumina, deCODE Genetics, and Standard BioTools, Inc., with automation partner support from Tecan. The data generated from these first 30,000 samples will be made available by UK Biobank immediately to the scientific research community upon completion and when the resulting data has undergone quality control, expected in the second half 2025.

For the data generated from an additional 20,000 samples, in alignment with UK Biobank’s standard practice, members of the industry consortium will have a period of exclusive access. Industry participants include deCODE Genetics and pharma collaborators GSK, Johnson & Johnson, and Novartis. Following that period, the data will be made available by UK Biobank to the wider scientific research community. Illumina anticipates that additional companies will join the consortium.

Professor Sir Rory Collins, Principal Investigator and chief executive of UK Biobank said: “This addition of increasingly rich proteomics data will help researchers paint an even more dynamic picture of how an individual’s genetics, environment and lifestyle come together to impact the development of different diseases.”

“This project complements the work of the UK Biobank Pharma Proteomics Project, by providing additional proteomic assay data for 50,000 of the UK Biobank volunteers’ blood samples. I am excited to see how the global scientific community will use these different sources of data to make leaps forward in the development of new ways to prevent and treat a wide range of diseases.”

“Proteomics is entering a transformative era, with the human health impact constrained to date by the limits of legacy technologies,” said Michael Egholm, PhD, chief executive officer of Standard BioTools Inc. “Today marks a critical milestone, as we seamlessly integrate DNA-based SOMAmers’ unparalleled multiplexing capacity with the leading NGS platform, and unlock the power of the UK Biobank to accelerate human health.”

The Illumina Protein Prep assay detects 9000 unique human proteins powered by 11,000 SOMAmer (Slow Off-rate Modified Aptamers) reagents, enabling sample-to-analysis proteomics discovery studies. The solution has been in early access limited release with customers, detecting 6000 human proteins, and is compatible with the NovaSeq X, NovaSeq X Plus, and NovaSeq 6000 Systems, enabling multiomics on a single platform. The solution will launch in the first half of 2025.

Use of forward-looking statements

This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) challenges inherent in developing and launching new products and services, including modifying and scaling manufacturing operations, and reliance on third-party suppliers for critical components; (ii) our ability to manufacture robust instrumentation and consumables; and (iii) the acceptance by customers of our newly launched products, which may or may not meet our and their expectations, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts’ expectations, or to provide interim reports or updates on the progress of the current quarter.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.

Contacts

Investors:
Salli Schwartz
858-291-6421
IR@illumina.com

Media:
Christine Douglass
PR@illumina.com

View original content:https://www.prnewswire.com/news-releases/illumina-launches-pilot-proteomics-program-with-uk-biobank-and-biopharma-collaborators-to-analyze-50-000-samples-302348923.html

SOURCE Illumina, Inc.

Technology

TapestryHealth and Third Eye Health Announce Strategic Partnership

Published

57 minutes ago

January 13, 2025

Undeniable synergies accelerate growth while exponentially improving care

STRATFORD, Conn., Jan. 13, 2025 /PRNewswire/ — TapestryHealth is excited to announce a new strategic partnership with Third Eye Health, a move that will enhance the technical capabilities of Third Eye’s clinicians while significantly expanding TapestryHealth’s reach into hundreds of additional post-acute care facilities across the United States.

The partnership will allow Tapestry to offer Third Eye Health’s best-in-class virtual care solution to its customers to provide on demand care on nights and weekends as part of Tapestry’s comprehensive technology and provider solution for creating an integrated 24/7 safety net wrapped around each resident. This will expand the technical capabilities for the clinicians on the Third Eye Health team.

“TapestryHealth has evolved from a technology-enabled telemedicine provider into one of the nation’s leading technology companies serving the post-acute care sector,” said Mordy Eisenberg, Co-Founder and Chief Growth & Product Officer of TapestryHealth. “Given our origins in telemedicine, we were often viewed as competitors to Third Eye Health. However, this partnership makes far more sense. Today, Tapestry offers the most comprehensive suite of healthcare technologies for skilled nursing facilities (SNFs) across the country. By integrating these technologies, we empower Third Eye’s clinicians to transition from being reactive responders to proactive care providers and allow us to offer Third Eye’s proven, vetted telehealth solution to our customers.”

Dan Herbstman, Co-Founder and CEO of Third Eye Health, echoed this sentiment: “The synergies between our two companies are undeniable. Tapestry has a deep understanding of our business and the advanced technology to elevate our service capabilities immediately. With our extensive national network and established presence in the post-acute care space, we are uniquely positioned to accelerate Tapestry’s growth while enhancing the quality of care provided to tens of thousands of elderly residents. This partnership truly exemplifies a win-win scenario.”

The collaboration began in November 2024, with both teams working closely to integrate their respective strengths. In a joint statement, Dr. Zahra Shariff, Chief Medical Officer of Third Eye Health, and Dr. Hans Jenkins, Chief Medical Officer at TapestryHealth, said, “This partnership will positively impact thousands of nursing home residents by offering a higher standard of care and providing hospitals with trusted post-acute facilities capable of delivering advanced 24/7 medical services.”

About TapestryHealth

TapestryHealth is the leader in monitoring and managing the health risk of the nation’s chronically ill senior population, delivering daily patient-centric health risk analytics, monthly health assessments and continuous vitals monitoring.

TapestryHealth is working in collaboration with its provider partners and in strategic alignment with public and private payors to deploy an integrated platform of technology and services which accelerate care interventions to patients and help bolster clinical capacity in long term care settings. Learn more at tapestryhealth.com.

About Third Eye Health
Third Eye Health is the leading virtual care provider and platform in the post-acute and long-term care settings. The company is focused on providing expert medical care at the bedside, ensuring the patient and resident gets the right care, at the right place at the right time to help prevent unnecessary trips to the hospital. During nights, weekends and holidays, Third Eye Health offers immediate virtual access to post-acute experienced physicians, nurse practitioners and physician assistants through its proprietary technology, integrated into workflow and existing electronic health records systems, paired with a care coordination system and analytics and reporting platform. Third Eye Health is growing rapidly with almost 1,000 customers, including the leading skilled nursing, senior living, primary care provider groups, accountable care organizations, health systems and insurers.

Contact: Mordy Eisenberg
meisenberg@tapestryhealth.com (845) 517-7842

View original content to download multimedia:https://www.prnewswire.com/news-releases/tapestryhealth-and-third-eye-health-announce-strategic-partnership-302349542.html

SOURCE TapestryHealth

Technology

Wealth Access Announces Integration with Q2’s Digital Banking Platform

Published

57 minutes ago

January 13, 2025

Financial Institutions can now provide data insights solution to account holders through Q2’s Digital Banking Platform

NASHVILLE, Tenn., Jan. 13, 2025 /PRNewswire/ — Wealth Access, the leading customer data insights platform that unifies and enriches data to power hyper-personalized experiences for financial institutions, today announced an integration with Q2’s Digital Banking Platform, via the Q2 Partner Accelerator Program. Q2 Holdings, Inc. (NYSE: QTWO) is a leading provider of digital transformation solutions for financial services.

Wealth Access’ integration with the Q2 Digital Banking Platform allows financial institutions to access their data through a single entry point. Through intelligent data unification across multiple systems, the platform generates dynamic balance sheets, allowing service teams to break down silos, view each client’s complete financial history, and collaborate across business lines. Wealth Access delivers deep insights that fuel hyper-personalized banking interactions, strengthen customer loyalty, and drive increased revenue.

The Q2 Partner Accelerator Program, through the Q2 Innovation Studio, allows in-demand financial services companies who are leveraging the Q2 Software Development Kit (SDK) to pre-integrate their technology to the Q2 Digital Banking Platform. This enables financial institutions to work with these partners, purchase their solutions and rapidly deploy their standardized integrations to their customers.

Lisa Fulton, COO at Lake City Bank, said, “At Lake City Bank, relationships and innovation are our foundation. Our integrations with Wealth Access and Q2 embody this commitment, enabling us to deliver an accessible digital banking solution with a seamless Wealth Advisory customer experience.”

“Bankers continue to grapple with data silos, isolating valuable customer information and disrupting the customer experience,” said David Benskin, CEO and founder of Wealth Access. “Our platform unifies and enriches the bank’s existing data to drive more effective decision-making and enhance customer experiences. Through our Q2 integration, Wealth Access is helping bankers unlock greater revenue potential and maximize customer experiences.”

“We’re excited to welcome Wealth Access to the Q2 Accelerator Partner Program to make integrated wealth advisory services available to interested financial institutions and their end customers through the Q2 Digital Banking Platform,” Johnny Ola, SVP of Q2 Innovation Studio at Q2 said. “It’s great to see the collaboration between Wealth Access and Lake City Bank to offer these capabilities and services.”

To learn more about Wealth Access and the Q2 Innovation Studio Partner Accelerator Program, please click here.

About Wealth Access

Wealth Access is the leading wealth data insights platform, pioneering the transformation of wealth management in banking. By intelligently unifying records across multiple systems, Wealth Access creates living balance sheets that enable service teams to see each client’s complete financial story, work across business lines to improve customer loyalty and drive higher revenue. As a result of its innovative enterprise-class solutions, Wealth Access today supports a variety of clients from RIAs, trust companies, brokers, regional and national banks.

About Q2 Holdings, Inc.

Q2 is a leading provider of digital transformation solutions for financial services, serving banks, credit unions, alternative finance companies, and fintechs in the U.S. and internationally. Q2 enables its financial institution and fintech customers to provide comprehensive, data-driven digital engagement solutions for consumers, small businesses and corporate clients. Headquartered in Austin, Texas, Q2 has offices worldwide and is publicly traded on the NYSE under the stock symbol QTWO. To learn more, please visit Q2.com. Follow us on LinkedIn and X to stay up to date.

View original content to download multimedia:https://www.prnewswire.com/news-releases/wealth-access-announces-integration-with-q2s-digital-banking-platform-302349408.html

SOURCE Wealth Access

Technology

Baseus Wins Three Prestigious Awards Following CES 2025 Innovation Honors

Published

57 minutes ago

January 13, 2025

LAS VEGAS, Jan. 13, 2025 /PRNewswire/ — Building on the momentum of winning two CES Innovation Awards earlier this year, Baseus has achieved yet another milestone by securing three additional prestigious awards at CES 2025. These accolades reinforce Baseus’ position as a leader in the consumer electronics industry and highlight its unwavering commitment to user-centric innovation.

Award-Winning Products: A Testament to Excellence

CES Innovation Awards Honorees

The CES Innovation Awards, known for celebrating outstanding design and engineering in consumer technology, recognize groundbreaking innovation and products that significantly benefit users. Baseus’ recognition as a two-time honoree in 2025 showcases its technological leadership and dedication to enhancing modern lifestyles.

Baseus EnerGeek MiFi Power Bank

The Baseus EnerGeek MiFi Power Bank was named one of the CES Innovation Awards 2025 honorees for its groundbreaking innovation in mobile power solutions. This 3-in-1 67W power bank is perfect for both leisure and business travel, offering seamless cross-regional 4G connectivity for up to 10 devices across 100+ countries. Its eSIM-enabled design allows users to manage and recharge data effortlessly via the Baseus app. Compact and lightweight, the power bank boasts a 20,000mAh capacity, delivering reliable power alongside flexible, customizable mobile internet data plans.

Baseus Spacemate Series 11-in-1 (Mac) Docking Station

The Baseus Spacemate Series 11-in-1 (Mac) Docking Station, a CES Innovation Awards 2025 honoree, redefines efficient workspaces with 4K@60Hz triple display support for macOS powered by DisplayLink technology. It delivers superior productivity with 10Gbps data transfer, 100W PD fast charging, and a sleek upright design with a magnetic base for better cable management. The built-in LED screen displays real-time connection status, while a screen-lock button ensures data security, seamlessly blending performance, organization, and privacy into one innovative device.

CES Picks Awards 2025 – TechRadar Pro Picks

The TechRadar Pro Picks Award celebrates brands that lead the industry with innovation and creative solutions. Judged by a panel of seasoned industry experts, this award recognizes the best new products showcased at CES.

According to TechRadar Pro’s editorial team, the award honors exceptional achievements across consumer technology, custom installations, and groundbreaking innovations that enhance businesses of all sizes. Baseus was among the standout winners, a reflection of its dedication to creating practical, reliable, and user-focused solutions.

Baseus Spacemate Series 11-in-1 (Mac) Docking Station

Winning the TechRadar Pro Picks Award, the Baseus Spacemate Series 11-in-1 (Mac) Docking Station raises the bar in modern workspaces with its versatile features and productivity-focused design.

Baseus Nomos Qi2 5-in-1 140W Desktop Charger

The Nomos Qi2 5-in-1 140W Desktop Charger, among the other product offerings honored with the TechRadar Pro Picks Award, is a must-have for hybrid workspaces. Featuring five high-performance ports and Baseus’ advanced BSFT (Baseus Safe Fast Charging) technology, it delivers unmatched speed, safety, and reliability—perfectly tailored to meet the demands of modern professionals.

Trusted Reviews Best in Show CES 2025

Baseus Spacemate Series 11-in-1 (Mac) Docking Station

The Trusted Reviews Best in Show Award is a hallmark of innovation and excellence, celebrating the most deserving technology at CES. The Baseus Spacemate Docking Station captured this coveted award for its cutting-edge functionality, elegant design, and unparalleled performance.

Trusted Reviews commended the product’s ability to push its category forward, providing professionals with an exceptional tool tailored to their needs. Winners of this award receive the Trusted Reviews seal of approval, benefiting from coverage across the platform’s website and social media channels, which reach millions of readers globally.

From Innovation to Industry Leadership: Baseus Continues to Shine

The five prestigious awards garnered at CES 2025 further cement Baseus’ position as an industry leader. With two CES Innovation Awards, two TechRadar Pro Picks Awards, and the Trusted Reviews Best in Show Award, Baseus showcases its unwavering dedication to innovation and excellence.

Guided by its philosophy, “Base On User,” Baseus remains committed to redefining technology with practical and reliable solutions that empower users worldwide. As the brand continues to set new benchmarks, it reaffirms its dedication to shaping the future of consumer electronics.

About Baseus

Founded in 2011, Baseus was born out of utmost care for users. The company embodies its slogan: Practical. Reliable. Base on User. This shows the pursuit of ultimate practicality to solve users’ problems with outstanding design and fashionable appearances that also reflect reliability, high quality, and cost-effectiveness. Baseus delivers a variety of products – including Portable Chargers, Desktop Chargers, Wall Chargers, Wireless Earbuds, and Docking Stations. Chosen by 300 million users and providing 6 billion services, Baseus delivers over 100 million practical and aesthetic products each year, continuously enhancing users’ sense of fulfillment. Join the Baseus family today to see a new world of technological innovation.

Media Contact:
Name: Baseus PR Team
Phone: +1 (213) 512-7063
Email: pr@baseus.com
Baseus Technology (HK) Co., Ltd

View original content to download multimedia:https://www.prnewswire.com/news-releases/baseus-wins-three-prestigious-awards-following-ces-2025-innovation-honors-302348990.html

SOURCE Baseus Technology (HK) Co., Ltd